Antibody-conjugates for targeting of tumours expressing Trop-2
The present invention concerns antibody-conjugate having general structure (2): AB-[(L 6 )-{Z—(L 1 ) n —(L 2 ) o —(L 3 ) p —(L 4 ) q -D} xx ] yy (2) wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.
1. An antibody-conjugate according to general structure (2):
AB-[(L 6 )-{Z—(L 1 ) n —(L 2 ) o —(L 3 ) p —(L 4 ) q -D} xx ] yy (2)
wherein:
AB is an antibody capable of targeting Trop-2-expressing tumours;
L 1 , L 2 , L 3 and L 4 are each individually linkers that together link Z to D;
n, o, p and q are each individually 0 or 1, provided that n+0+p+q is 1, 2, 3 or 4;
Z is a connecting group;
L′ is —GlcNAc(Fuc) w —S—(L 7 ) w —, wherein S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine and Fuc is fucose, w is 0 or 1, w′ is 0, 1 or 2 and L 7 is —N(H)C(O)CH 2 —, —N(H) C (O) CF 2 — or —CH 2 —;
D is selected from the group consisting of a taxane, an anthracycline, a camptothecin, an epothilone, a mitomycin, a combretastatin, a vinca alkaloid, a maytansinoid, an enediyne, a duocarmycin, a tubulysin, an amatoxin, a bleomycin, a dolastatin, an auristatin, a pyrrolobenzodiazepine dimer, an indolinobenzodiazepine dimer, a radioisotope, a kinase inhibitor, a mitogen-activated protein kinase (MEK) inhibitor, and a kinesin spindle protein (KSP) inhibitor;
xx is 1 or 2;
yy is 1, 2, 3 or 4, and
wherein the antibody is a Huk5-70-2 antibody comprising a light chain variable region and a heavy chain variable region wherein the light chain variable region comprises the amino acid sequence of SEQ ID NO: 1 and the heavy chain comprises the amino acid sequence of SEQ ID NO: 2.
2. The antibody-conjugate according to claim 1 , wherein Z comprises the reaction product of a click reaction or cycloaddition reaction.
3. The antibody-conjugate according to claim 2 , wherein Z comprises a triazole moiety.
4. The antibody-conjugate according to claim 3 , wherein Z is according (Ze), (Zf) or (Zi):
wherein:
R 15 is independently selected from the group consisting of hydrogen, halogen, —OR 16 , —NO 2 , —CN, —S(O) 2 R 16 , C 1 -C 24 alkyl, C 6 -C 24 (hetero) aryl, C 7 -C 24 alkyl (hetero) aryl and C 7 -C 24 (hetero) arylalkyl, or two R 15 groups are taken together to form a annulated cycloalkyl or an annulated (hetero) arene substituent, wherein R 16 is independently selected from the group consisting of hydrogen, halogen, C 1 -C 24 alkyl, C 6 -C 24 (hetero) aryl, C 7 -C 24 alkyl (hetero) aryl and C 7 -C 24 (hetero) arylalkyl;
X 10 is C (R 31 ) 2, O, S or NR 31 , wherein each R 31 is individually R 15 or —(L 1 ) n —(L 2 ) o —(L 3 ) p —(L 4 ) q -D;
u and u′ are each individually 0, 1, 2, 3, 4 or 5, provided that u+u′ is 5; and
v is 8, 9 or 10.
5. The antibody-conjugate according to claim 1 , wherein the GlcNAc (Fuc) w moiety is directly bonded to a peptide chain of the antibody AB.
6. The antibody-conjugate according to claim 1 , wherein n, o, and p are each 1.
7. The antibody-conjugate according to claim 1 , wherein:
(a) linker L 1 is represented by:
-(W) k -(A) d -(B) c -(A) f -(B) g -(C(O)) g -, or
-(W) k -(A) d -(B) c -(A) f -(C(O)) g -N*[-(A) d -(B) e -(A) f -(C(O)) g -] 2 ,
wherein:
d and d′ are individually 0 or 1;
e and e′ are individually an integer in the range 1-10;
f and f′ are individually 0, or 1;
g and g′ are individually an integer in the range 0-10;
k is 0 or 1 with the proviso that if k is 1 then d is 0;
A is a sulfamide group according to structure (23):
wherein a is 0 or 1, and R 13 is selected from the group consisting of hydrogen, C 1 -C 24 alkyl, C 3 -C 24 cycloalkyl, C 2 -C 24 (hetero) aryl, C 3 -C 24 alkyl (hetero) aryl and C 3 -C 24 (hetero) arylalkyl, the C 1 -C 24 alkyl, C 3 -C 24 cycloalkyl, C 2 -C 24 (hetero) aryl, C 3 -C 24 alkyl (hetero) aryl and C 3 -C 24 (hetero) arylalkyl optionally substituted and optionally interrupted by one or more heteroatoms selected from O, S and NR 14 wherein R 14 is independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl, or R 13 is D connected to the N via a spacer moiety;
W is —OC(O)—, —C(O)O—, —C(O)NH—, —NHC(O)—, —OC(O)NH—, —NHC(O)O—, —C(O)(CH 2 ) m C(O)—, —C(O)(CH 2 ) m C(O)NH— or —(4-Ph)CH 2 NHC(O)(CH 2 ) m C(O)NH—, wherein m is an integer in the range 0-10;
B is a —CH 2 —CH 2 —O— or a —O—CH 2 —CH 2 — moiety, or (B) e is a —(CH 2 —CH 2 —O) e1 —CH 2 —CH 2 — moiety, wherein e1 is an integer in the range 1-10;
N* is a branching nitrogen atom, to which two instances of -(A) d -(B) e -(A)-(C(O)) g - are connected and both (C(O)) g moieties are connected to —(L 2 ) o —(L 3 ) p —(L 4 ) q -D;
and/or
(b) linker L 2 is a peptide spacer;
and/or
(c) linker L 3 is a self-immolative spacer;
and/or
(d) linker L 4 is an aminoalkanoic acid spacer according to the structure —NR 22 (C x -alkylene)-C(O)—, wherein x is an integer in the range 1-20 and R 22 is H or C 1 -C 4 alkyl; or
linker L 4 is a an ethyleneglycol spacer according to the structure —NR 22 —(CH 2 —CH 2 —O) e6 —(CH 2 ) e7 —C(O)—, wherein e6 is an integer in the range 1-10, e7 is an integer in the range 1-3 and R 22 is H or C 1 -C 4 alkyl; or
linker L 4 is a diamine spacer according to the structure —NR 22 —(C x -alkylene)-NR 22 —, wherein x is an integer in the range 1-10 and R 22 is H or C 1 -C 4 alkyl.
8. The antibody-conjugate according to claim 7 , wherein the spacer moiety is -(B) g -(C(O)) g —(L 2 ) o —(L 3 ) p —(L 4 ) q -.
9. The antibody-conjugate according to claim 7 , wherein peptide spacer is a dipeptide represented by general structure (27):
wherein R 17 is CH 3 or CH 2 CH 2 CH 2 NHC(O)NH 2 .
10. The antibody-conjugate according to claim 7 , wherein the self-immolative spacer is a para-aminobenzyloxycarbonyl (PABC) derivative according to structure (25):
wherein R 3 is H, R 4 or C (O) R 4 , wherein R 4 is C 1 -C 24 (hetero) alkyl groups, C 3 -C 10 (hetero) cycloalkyl groups, C 2 -C 10 (hetero) aryl groups, C 3 -C 10 alkyl (hetero) aryl groups and C 3 -C 10 (hetero) arylalkyl groups, which are optionally substituted and optionally interrupted by one or more heteroatoms selected from O, S and NR 5 wherein R 5 is independently selected from the group consisting of hydrogen and C 1 -C 4 alkyl groups.
11. The antibody-conjugate according to claim 10 , wherein R 3 is H or C (O) R 4 .
12. The antibody-conjugate according to claim 11 , wherein R 4 is 4-methyl-piperazine or morpholine.
13. The antibody-conjugate according to claim 1 , which has a structure of (XXIII):
wherein the wavy line indicates the connection to Z;
R 17 is CH 3 or CH 2 CH 2 CH 2 NHC (O) NH 2 ; and
x is an integer in the range 1-10.
14. The antibody-conjugate according to claim 1 , wherein D is selected from the group consisting of an auristatin, an amatoxin, an enediyne, a camptothecin and a bleomycin.
15. The antibody-conjugate according to claim 1 , wherein Z comprises a triazole moiety and is according to structure (Zj):
wherein:
R 15 is independently selected from the group consisting of hydrogen, halogen, —OR 16 , —NO 2 , —CN, —S(O) 2 R 16 , C 1 -C 24 alkyl, C 5 -C 24 (hetero) aryl, C 7 -C 24 alkyl (hetero) aryl and C 7 -C 24 (hetero) arylalkyl, or two R 15 groups are taken together to form an annulated cycloalkyl or an annulated (hetero) arene, wherein R 16 is independently selected from the group consisting of hydrogen, halogen, C 1 -C 24 alkyl, C 6 -C 24 (hetero) aryl, C 7 -C 24 alkyl (hetero) aryl and C 7 -C 24 (hetero) arylalkyl;
R 18 is independently selected from the group consisting of hydrogen, halogen, C 1 -C 24 alkyl, C 6 -C 24 (hetero) aryl, C 7 -C 24 alkyl (hetero) aryl and C 7 -C 24 (hetero) arylalkyl;
R 19 is selected from the group consisting of hydrogen, —(L 1 ) n —(L 2 ) o —(L 3 ) p —(L 4 ) q —D, halogen, C 1 -C 24 alkyl, C 6 -C 24 (hetero) aryl, C 7 -C 24 alkyl (hetero) aryl and C 7 -C 24 (hetero) arylalkyl, the alkyl group optionally being interrupted by one or more hetero-atoms selected from the group consisting of O, N and S; and
l is an integer in the range 0 to 10.
16. The antibody-conjugate according to claim 10 , wherein:
(I) AB is Huk5-70-2; S is GalNAc; w′ is 0; R 15 , R 18 , and R 19 are each H; l is 1; n, o, and p are each 1; q is 0; L 1 is —O—C(O)—NH—S(O) 2 —NH—((CH 2 ) 2 O) 2 —C(O)—N* [(CH 2 ) 2 O—] 2 ; L 2 is Val-Cit; L 3 is according to structure (25) with R 3 is H; D is MMAE; xx is 1; and yy is 2;
(II) AB is Huk5-70-2; S is GalNAc; w′ is 0; R 15 , R 18 , and R 19 are each H; 1 is 1; n, o, and p are each 1; q is 0; L 1 is —O—C(O)—NH—S(O) 2 —NH—((CH 2 ) 2 O) 2 —C(O)—N* [(CH 2 ) 2 O—] 2 ; L 2 is Val-Cit; L 3 is according to structure (25) with R 3 is H; D is SN-38; xx is 1; and yy is 2;
(III) AB is Huk5-70-2; S is GalNAc; w′ is 0; R 15 , R 18 , and R 19 are each H; 1 is 1; n, o, and p are each 1; q is 1; L 1 is —O—C(O)—NH—S(O) 2 —NH—((CH 2 ) 2 O) 2 —C(O)—N* [(CH 2 ) 2 O-] 2 ; L 2 is Val-Cit; L 3 is according to structure (25) with R 3 is H; L 4 is —NR 22 -(C x -alkylene)-NR 22 —, wherein x is 5 and R 22 is Me; D is B-amanitin; xx is 1; and yy is 2;
(IV) AB is Huk5-70-2; S is GalNAc; w′ is 0; R 15 , R 18 , and R 19 are each H; l is 1; n, o, and p are each 1; q is 0; L 1 is —O—C(O)—NH—S(O) 2 —NH—((CH 2 ) 2 O) 2 —C(O)—N* [(CH 2 ) 2 O-] 2 ; L 2 is Val-Cit; L 3 is according to structure (25) with R 3 is H; D is bleomycin; xx is 1; and yy is 2;
(V) AB is Huk5-70-2; S is GalNAc; w′ is 0; R 15 , R 18 , and R 19 are each H; 1 is 1; n, o, and p are each 1; q is 0; L 1 is —O—C(O)—NH—S(O) 2 —NH—((CH 2 ) 2 O) 2 —C(O)—N* [(CH 2 ) 2 O-] 2 ; L 2 is Val-Cit; L 3 is according to structure (25) with R 3 is H; D is calicheamicin; xx is 1; and yy is 2.
17. The antibody-conjugate according to claim 14 , wherein the enediyne is selected from the group consisting of calicheamicin, speramicin, shishijimicin and namenamicin.
18. The antibody-conjugate according to claim 14 , wherein the auristatin is selected from the group consisting of MMAE, MMAF or MMAD.
19. The antibody-conjugate according to claim 14 , wherein the amatoxin is selected from the group consisting of α-amanitin, β-amanitin, γ-amanitin, ε-amanitin, amanullin, amanullinic acid, amaninamide, amanin and proamanullin.
20. The antibody-conjugate according to claim 14 , wherein the camptothecin is SN-38.
21. The antibody-conjugate according to claim 14 , wherein D is bleomycin.